


ENV-101

ENV-101 is a small molecule Hedgehog signaling inhibitor that is being developed as a precision therapy in multiple types of cancer where the Hedgehog pathway is implicated as a driver of the disease.

Six completed studies have characterized the pharmaceutical properties, including PK/PD in patients with advanced solid tumors and demonstrated a manageable safety profile.

Scan the QR code below to learn more about ENV-101 for PTCH-1 LOF cancer treatment.



Clinical Trials

We are developing ENV-101 for patients with tumor mutations in the Hedgehog pathway, which affect approximately 2% of all cancers. Mutations in this pathway can aberrantly activate downstream signaling resulting in proliferation, survival, and metastasis of cancer cells. ENV-101 may potentially inhibit the activity of the Hedgehog pathway, which may have a significant benefit on the lives of cancer patients with these mutations.

Who can participate?

Any person 18 years or older.

Any person who has a PTCH-1 LOF mutation.

Any person who has an advanced solid tumor.

xCures Partnership

Endeavor is partnered with xCures. Regardless of your eligibility for the Endeavor trial, xCures will still send you a list of other treatment options that could work for your cancer mutation. This means that even if you are not eligible for the Endeavor trial, you will receive a list of other treatment options that could work against your cancer mutation.

How can I help if I can't participate?

Spread the word. If you have a family member/friend who you think may qualify for this trial, reach out.

The xCures logo, featuring a stylized 'x' in blue and 'Cures' in black, positioned in the bottom right corner of the page. The background of the entire page features a light blue DNA double helix and network-like patterns.